Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS(G12C) mutations.

Barlesi F, Yao W, Duruisseaux M, Doucet L, Azkárate Martínez A, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, MichenzIe MF, Yang W, Meade JN, Korytowsky B, Mok TSK, KRYSTAL-12 Investigators

Open source

DOI: 10.1080/14796694.2026.2719409
Published: 2026 Sep 16
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2719409,
  title = {Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS(G12C) mutations.},
  author = {Barlesi F and Yao W and Duruisseaux M and Doucet L and Azkárate Martínez A and Gregorc V and Juan-Vidal O and Lu S and De Bondt C and de Marinis F and Linardou H and Kim YC and Jotte R and Felip E and Lo Russo G and Reck M and MichenzIe MF and Yang W and Meade JN and Korytowsky B and Mok TSK and KRYSTAL-12 Investigators},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2719409},
  url = {https://doi.org/10.1080/14796694.2026.2719409}
}

RIS

TY  - JOUR
TI  - Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS(G12C) mutations.
AU  - Barlesi F
AU  - Yao W
AU  - Duruisseaux M
AU  - Doucet L
AU  - Azkárate Martínez A
AU  - Gregorc V
AU  - Juan-Vidal O
AU  - Lu S
AU  - De Bondt C
AU  - de Marinis F
AU  - Linardou H
AU  - Kim YC
AU  - Jotte R
AU  - Felip E
AU  - Lo Russo G
AU  - Reck M
AU  - MichenzIe MF
AU  - Yang W
AU  - Meade JN
AU  - Korytowsky B
AU  - Mok TSK
AU  - KRYSTAL-12 Investigators
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2719409
UR  - https://doi.org/10.1080/14796694.2026.2719409
ER  -

APA

F, B., W, Y., M, D., L, D., A, A. M., V, G., O, J., S, L., C, D. B., F, D. M., H, L., YC, K., R, J., E, F., G, L. R., M, R., MF, M., W, Y., JN, M., B, K., TSK, M., & Investigators, K. (2026). Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS(G12C) mutations.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2719409

Source records

pubmed · retrieved 2026-09-26T02:46:36.479Z
europe-pmc · retrieved 2026-09-26T02:46:36.475Z